Physician

Fadi V Bedros, M.D.

According to 2025 Medicare claims, Fadi Bedros, M.D. (NPI: 1407893290) practices nephrology in the Manhattan, KS market, with the plurality of this provider's patient population coming from Riley, KS. This provider's primary affiliated billing organization is MY KIDNEY CENTER, LLC (NPI: 1770823668; TIN: 900916210) and primary practice location at 66502-2770. Bedros is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Bedros' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 714 traditional Medicare patients, billed 4,344 HCPCS/CPT codes, and received $311,870 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,066 prescription claims across 361 beneficiaries totaling $149,611 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2023 DME data shows 25 claims. Open Payments data shows 5 records totaling $341. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $327,412 and ending at $311,870. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,719 to $5,973.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	626	6,185	$327,412
2016	538	5,531	$239,737
2017	562	6,673	$264,330
2018	578	5,434	$250,655
2019	824	6,310	$343,085
2020	878	6,697	$402,037
2021	842	5,525	$415,383
2022	808	4,439	$340,942
2023	776	4,297	$305,013
2024	714	4,344	$311,870

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	203	1,566	$142,879
2016	180	1,160	$134,335
2017	208	1,251	$114,224
2018	237	1,662	$95,104
2019	275	2,042	$139,216
2020	346	2,613	$130,397
2021	354	2,487	$137,839
2022	305	1,753	$107,527
2023	299	1,559	$120,343
2024	361	2,066	$149,611

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	43	$2,647
2016	N/R	19	$1,799
2017	N/R	19	$1,210
2018	N/R	74	$1,472
2019	N/R	13	$133
2020	N/R	25	$525
2021	N/R	49	$1,970
2022	N/R	57	$16,593
2023	N/R	25	$10,902
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	58	413	$256
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	88	88	$159
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	131	220	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	476	895	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	231	324	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	91	3,414	$61,703
Jardiance	Empagliflozin	35	1,164	$23,579
Veltassa	Patiromer Calcium Sorbitex	19	744	$12,353
Clinolipid	Fat Emulsion/Olive/Soy/Phospho	52	361	$11,537
Eliquis	Apixaban	13	182	$3,859

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$341	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Fadi V. Bedros, M.D.?

Tedicare shows public-source Medicare data for Fadi V. Bedros, M.D. (NPI 1407893290), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Fadi V. Bedros, M.D. have ACO affiliation data?

Fadi V. Bedros, M.D. is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Fadi V. Bedros, M.D.?

Fadi V. Bedros, M.D. is linked to MY KIDNEY CENTER, LLC (billing NPI 1770823668) in the available physician profile data.

Does Fadi V. Bedros, M.D. have Open Payments data?

Fadi V. Bedros, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.